The iconic rise of Viagra has long been a benchmark Adult of pharmaceutical success, but its legacy within the broader industry now raises questions about long-term returns . Alternative versions are eroding market share, prompting concerns that supporting companies heavily reliant to Viagra's previous standing could be a problematic strategy, espe